Rise of a lifestyle drug: weight loss jabs will force more than just food brands to pivot
Briefly

GLP-1 medications have seen significant adoption, with 12% of Americans using them for managing conditions like diabetes and 40% for weight loss. Over the past few years, Novo Nordisk reported $50 billion in sales, primarily from the US. Experts predict the user base will grow globally, reaching 31.5 million users by 2035. The influence of GLP-1 extends beyond healthcare into lifestyle choices, shaping consumer behavior across sectors such as tourism, fashion, and food, prompting numerous industries to adapt strategies accordingly.
The emergence of GLP-1 medications, originally popular in the US, is now a global phenomenon, projected to grow to 31.5 million users by 2035.
The impact of GLP-1 medications on consumer behavior transcends the healthcare sector, influencing various industries such as food, beauty, tourism, and technology.
As appetite decreases due to GLP-1 use, consumer patterns undergo significant transformations, affecting lifestyle choices and consumption habits far beyond simple weight loss.
Industry leaders recognize that the true disruption in advertising is driven by GLP-1 medications rather than emerging technologies like AI or GPT.
Read at The Drum
[
|
]